The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Tetravalent Influenza Virus Lysate Vaccine Market Research Report 2025
Synopsis
Influenza virus split vaccine is made by inoculating chicken embryos with influenza virus strains recommended by the World Health Organization (WHO) and approved by the national drug administration department, cultured, harvested virus liquid, virus inactivated, purified, and cracked. For the prevention of influenza caused by this type of virus.
The global Tetravalent Influenza Virus Lysate Vaccine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Tetravalent Influenza Virus Lysate Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Tetravalent Influenza Virus Lysate Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Tetravalent Influenza Virus Lysate Vaccine include Hualan Vaccine, SINOVAC, Sanofi Pasteur, CSL Seqirus, GSK, Seqirus, Inc. and Shanghai Institute of Biological Products, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Tetravalent Influenza Virus Lysate Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tetravalent Influenza Virus Lysate Vaccine.
Report Scope
The Tetravalent Influenza Virus Lysate Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Tetravalent Influenza Virus Lysate Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Tetravalent Influenza Virus Lysate Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Hualan Vaccine
SINOVAC
Sanofi Pasteur
CSL Seqirus
GSK
Seqirus, Inc.
Shanghai Institute of Biological Products
Segment by Type
Aldult
Child
Segment by Application
Hospital
Clinic
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
China Taiwan
Australia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Tetravalent Influenza Virus Lysate Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Tetravalent Influenza Virus Lysate Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Influenza virus split vaccine is made by inoculating chicken embryos with influenza virus strains recommended by the World Health Organization (WHO) and approved by the national drug administration department, cultured, harvested virus liquid, virus inactivated, purified, and cracked. For the prevention of influenza caused by this type of virus.
The global Tetravalent Influenza Virus Lysate Vaccine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Tetravalent Influenza Virus Lysate Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Tetravalent Influenza Virus Lysate Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Tetravalent Influenza Virus Lysate Vaccine include Hualan Vaccine, SINOVAC, Sanofi Pasteur, CSL Seqirus, GSK, Seqirus, Inc. and Shanghai Institute of Biological Products, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Tetravalent Influenza Virus Lysate Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tetravalent Influenza Virus Lysate Vaccine.
Report Scope
The Tetravalent Influenza Virus Lysate Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Tetravalent Influenza Virus Lysate Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Tetravalent Influenza Virus Lysate Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Hualan Vaccine
SINOVAC
Sanofi Pasteur
CSL Seqirus
GSK
Seqirus, Inc.
Shanghai Institute of Biological Products
Segment by Type
Aldult
Child
Segment by Application
Hospital
Clinic
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
China Taiwan
Australia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Tetravalent Influenza Virus Lysate Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Tetravalent Influenza Virus Lysate Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Tetravalent Influenza Virus Lysate Vaccine Market Overview
1.1 Product Overview and Scope of Tetravalent Influenza Virus Lysate Vaccine
1.2 Tetravalent Influenza Virus Lysate Vaccine Segment by Type
1.2.1 Global Tetravalent Influenza Virus Lysate Vaccine Market Value Comparison by Type (2024-2030)
1.2.2 Aldult
1.2.3 Child
1.3 Tetravalent Influenza Virus Lysate Vaccine Segment by Application
1.3.1 Global Tetravalent Influenza Virus Lysate Vaccine Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Tetravalent Influenza Virus Lysate Vaccine Market Size Estimates and Forecasts
1.4.1 Global Tetravalent Influenza Virus Lysate Vaccine Revenue 2019-2030
1.4.2 Global Tetravalent Influenza Virus Lysate Vaccine Sales 2019-2030
1.4.3 Global Tetravalent Influenza Virus Lysate Vaccine Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Tetravalent Influenza Virus Lysate Vaccine Market Competition by Manufacturers
2.1 Global Tetravalent Influenza Virus Lysate Vaccine Sales Market Share by Manufacturers (2019-2024)
2.2 Global Tetravalent Influenza Virus Lysate Vaccine Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Tetravalent Influenza Virus Lysate Vaccine Average Price by Manufacturers (2019-2024)
2.4 Global Tetravalent Influenza Virus Lysate Vaccine Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Tetravalent Influenza Virus Lysate Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Tetravalent Influenza Virus Lysate Vaccine, Product Type & Application
2.7 Tetravalent Influenza Virus Lysate Vaccine Market Competitive Situation and Trends
2.7.1 Tetravalent Influenza Virus Lysate Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Tetravalent Influenza Virus Lysate Vaccine Players Market Share by Revenue
2.7.3 Global Tetravalent Influenza Virus Lysate Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Tetravalent Influenza Virus Lysate Vaccine Retrospective Market Scenario by Region
3.1 Global Tetravalent Influenza Virus Lysate Vaccine Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Tetravalent Influenza Virus Lysate Vaccine Global Tetravalent Influenza Virus Lysate Vaccine Sales by Region: 2019-2030
3.2.1 Global Tetravalent Influenza Virus Lysate Vaccine Sales by Region: 2019-2024
3.2.2 Global Tetravalent Influenza Virus Lysate Vaccine Sales by Region: 2025-2030
3.3 Global Tetravalent Influenza Virus Lysate Vaccine Global Tetravalent Influenza Virus Lysate Vaccine Revenue by Region: 2019-2030
3.3.1 Global Tetravalent Influenza Virus Lysate Vaccine Revenue by Region: 2019-2024
3.3.2 Global Tetravalent Influenza Virus Lysate Vaccine Revenue by Region: 2025-2030
3.4 North America Tetravalent Influenza Virus Lysate Vaccine Market Facts & Figures by Country
3.4.1 North America Tetravalent Influenza Virus Lysate Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Tetravalent Influenza Virus Lysate Vaccine Sales by Country (2019-2030)
3.4.3 North America Tetravalent Influenza Virus Lysate Vaccine Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Tetravalent Influenza Virus Lysate Vaccine Market Facts & Figures by Country
3.5.1 Europe Tetravalent Influenza Virus Lysate Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Tetravalent Influenza Virus Lysate Vaccine Sales by Country (2019-2030)
3.5.3 Europe Tetravalent Influenza Virus Lysate Vaccine Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Netherlands
3.6 Asia Pacific Tetravalent Influenza Virus Lysate Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Tetravalent Influenza Virus Lysate Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Tetravalent Influenza Virus Lysate Vaccine Sales by Country (2019-2030)
3.6.3 Asia Pacific Tetravalent Influenza Virus Lysate Vaccine Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Southeast Asia
3.6.9 China Taiwan
3.6.10 Australia
3.7 Latin America Tetravalent Influenza Virus Lysate Vaccine Market Facts & Figures by Country
3.7.1 Latin America Tetravalent Influenza Virus Lysate Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Tetravalent Influenza Virus Lysate Vaccine Sales by Country (2019-2030)
3.7.3 Latin America Tetravalent Influenza Virus Lysate Vaccine Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Tetravalent Influenza Virus Lysate Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Tetravalent Influenza Virus Lysate Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Tetravalent Influenza Virus Lysate Vaccine Sales by Country (2019-2030)
3.8.3 Middle East and Africa Tetravalent Influenza Virus Lysate Vaccine Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Tetravalent Influenza Virus Lysate Vaccine Sales by Type (2019-2030)
4.1.1 Global Tetravalent Influenza Virus Lysate Vaccine Sales by Type (2019-2024)
4.1.2 Global Tetravalent Influenza Virus Lysate Vaccine Sales by Type (2025-2030)
4.1.3 Global Tetravalent Influenza Virus Lysate Vaccine Sales Market Share by Type (2019-2030)
4.2 Global Tetravalent Influenza Virus Lysate Vaccine Revenue by Type (2019-2030)
4.2.1 Global Tetravalent Influenza Virus Lysate Vaccine Revenue by Type (2019-2024)
4.2.2 Global Tetravalent Influenza Virus Lysate Vaccine Revenue by Type (2025-2030)
4.2.3 Global Tetravalent Influenza Virus Lysate Vaccine Revenue Market Share by Type (2019-2030)
4.3 Global Tetravalent Influenza Virus Lysate Vaccine Price by Type (2019-2030)
5 Segment by Application
5.1 Global Tetravalent Influenza Virus Lysate Vaccine Sales by Application (2019-2030)
5.1.1 Global Tetravalent Influenza Virus Lysate Vaccine Sales by Application (2019-2024)
5.1.2 Global Tetravalent Influenza Virus Lysate Vaccine Sales by Application (2025-2030)
5.1.3 Global Tetravalent Influenza Virus Lysate Vaccine Sales Market Share by Application (2019-2030)
5.2 Global Tetravalent Influenza Virus Lysate Vaccine Revenue by Application (2019-2030)
5.2.1 Global Tetravalent Influenza Virus Lysate Vaccine Revenue by Application (2019-2024)
5.2.2 Global Tetravalent Influenza Virus Lysate Vaccine Revenue by Application (2025-2030)
5.2.3 Global Tetravalent Influenza Virus Lysate Vaccine Revenue Market Share by Application (2019-2030)
5.3 Global Tetravalent Influenza Virus Lysate Vaccine Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Hualan Vaccine
6.1.1 Hualan Vaccine Corporation Information
6.1.2 Hualan Vaccine Description and Business Overview
6.1.3 Hualan Vaccine Tetravalent Influenza Virus Lysate Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Hualan Vaccine Tetravalent Influenza Virus Lysate Vaccine Product Portfolio
6.1.5 Hualan Vaccine Recent Developments/Updates
6.2 SINOVAC
6.2.1 SINOVAC Corporation Information
6.2.2 SINOVAC Description and Business Overview
6.2.3 SINOVAC Tetravalent Influenza Virus Lysate Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 SINOVAC Tetravalent Influenza Virus Lysate Vaccine Product Portfolio
6.2.5 SINOVAC Recent Developments/Updates
6.3 Sanofi Pasteur
6.3.1 Sanofi Pasteur Corporation Information
6.3.2 Sanofi Pasteur Description and Business Overview
6.3.3 Sanofi Pasteur Tetravalent Influenza Virus Lysate Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Sanofi Pasteur Tetravalent Influenza Virus Lysate Vaccine Product Portfolio
6.3.5 Sanofi Pasteur Recent Developments/Updates
6.4 CSL Seqirus
6.4.1 CSL Seqirus Corporation Information
6.4.2 CSL Seqirus Description and Business Overview
6.4.3 CSL Seqirus Tetravalent Influenza Virus Lysate Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 CSL Seqirus Tetravalent Influenza Virus Lysate Vaccine Product Portfolio
6.4.5 CSL Seqirus Recent Developments/Updates
6.5 GSK
6.5.1 GSK Corporation Information
6.5.2 GSK Description and Business Overview
6.5.3 GSK Tetravalent Influenza Virus Lysate Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.5.4 GSK Tetravalent Influenza Virus Lysate Vaccine Product Portfolio
6.5.5 GSK Recent Developments/Updates
6.6 Seqirus, Inc.
6.6.1 Seqirus, Inc. Corporation Information
6.6.2 Seqirus, Inc. Description and Business Overview
6.6.3 Seqirus, Inc. Tetravalent Influenza Virus Lysate Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Seqirus, Inc. Tetravalent Influenza Virus Lysate Vaccine Product Portfolio
6.6.5 Seqirus, Inc. Recent Developments/Updates
6.7 Shanghai Institute of Biological Products
6.6.1 Shanghai Institute of Biological Products Corporation Information
6.6.2 Shanghai Institute of Biological Products Description and Business Overview
6.6.3 Shanghai Institute of Biological Products Tetravalent Influenza Virus Lysate Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Shanghai Institute of Biological Products Tetravalent Influenza Virus Lysate Vaccine Product Portfolio
6.7.5 Shanghai Institute of Biological Products Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Tetravalent Influenza Virus Lysate Vaccine Industry Chain Analysis
7.2 Tetravalent Influenza Virus Lysate Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Tetravalent Influenza Virus Lysate Vaccine Production Mode & Process
7.4 Tetravalent Influenza Virus Lysate Vaccine Sales and Marketing
7.4.1 Tetravalent Influenza Virus Lysate Vaccine Sales Channels
7.4.2 Tetravalent Influenza Virus Lysate Vaccine Distributors
7.5 Tetravalent Influenza Virus Lysate Vaccine Customers
8 Tetravalent Influenza Virus Lysate Vaccine Market Dynamics
8.1 Tetravalent Influenza Virus Lysate Vaccine Industry Trends
8.2 Tetravalent Influenza Virus Lysate Vaccine Market Drivers
8.3 Tetravalent Influenza Virus Lysate Vaccine Market Challenges
8.4 Tetravalent Influenza Virus Lysate Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Tetravalent Influenza Virus Lysate Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Tetravalent Influenza Virus Lysate Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Tetravalent Influenza Virus Lysate Vaccine Market Competitive Situation by Manufacturers in 2023
Table 4. Global Tetravalent Influenza Virus Lysate Vaccine Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Tetravalent Influenza Virus Lysate Vaccine Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Tetravalent Influenza Virus Lysate Vaccine Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Tetravalent Influenza Virus Lysate Vaccine Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Tetravalent Influenza Virus Lysate Vaccine Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Tetravalent Influenza Virus Lysate Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Tetravalent Influenza Virus Lysate Vaccine, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Tetravalent Influenza Virus Lysate Vaccine, Product Type & Application
Table 12. Global Key Manufacturers of Tetravalent Influenza Virus Lysate Vaccine, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Tetravalent Influenza Virus Lysate Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tetravalent Influenza Virus Lysate Vaccine as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Tetravalent Influenza Virus Lysate Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Tetravalent Influenza Virus Lysate Vaccine Sales by Region (2019-2024) & (K Units)
Table 18. Global Tetravalent Influenza Virus Lysate Vaccine Sales Market Share by Region (2019-2024)
Table 19. Global Tetravalent Influenza Virus Lysate Vaccine Sales by Region (2025-2030) & (K Units)
Table 20. Global Tetravalent Influenza Virus Lysate Vaccine Sales Market Share by Region (2025-2030)
Table 21. Global Tetravalent Influenza Virus Lysate Vaccine Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Tetravalent Influenza Virus Lysate Vaccine Revenue Market Share by Region (2019-2024)
Table 23. Global Tetravalent Influenza Virus Lysate Vaccine Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Tetravalent Influenza Virus Lysate Vaccine Revenue Market Share by Region (2025-2030)
Table 25. North America Tetravalent Influenza Virus Lysate Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Tetravalent Influenza Virus Lysate Vaccine Sales by Country (2019-2024) & (K Units)
Table 27. North America Tetravalent Influenza Virus Lysate Vaccine Sales by Country (2025-2030) & (K Units)
Table 28. North America Tetravalent Influenza Virus Lysate Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Tetravalent Influenza Virus Lysate Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Tetravalent Influenza Virus Lysate Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Tetravalent Influenza Virus Lysate Vaccine Sales by Country (2019-2024) & (K Units)
Table 32. Europe Tetravalent Influenza Virus Lysate Vaccine Sales by Country (2025-2030) & (K Units)
Table 33. Europe Tetravalent Influenza Virus Lysate Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Tetravalent Influenza Virus Lysate Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Tetravalent Influenza Virus Lysate Vaccine Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Tetravalent Influenza Virus Lysate Vaccine Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Tetravalent Influenza Virus Lysate Vaccine Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Tetravalent Influenza Virus Lysate Vaccine Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Tetravalent Influenza Virus Lysate Vaccine Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Tetravalent Influenza Virus Lysate Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Tetravalent Influenza Virus Lysate Vaccine Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Tetravalent Influenza Virus Lysate Vaccine Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Tetravalent Influenza Virus Lysate Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Tetravalent Influenza Virus Lysate Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Tetravalent Influenza Virus Lysate Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Tetravalent Influenza Virus Lysate Vaccine Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Tetravalent Influenza Virus Lysate Vaccine Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Tetravalent Influenza Virus Lysate Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Tetravalent Influenza Virus Lysate Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Tetravalent Influenza Virus Lysate Vaccine Sales (K Units) by Type (2019-2024)
Table 51. Global Tetravalent Influenza Virus Lysate Vaccine Sales (K Units) by Type (2025-2030)
Table 52. Global Tetravalent Influenza Virus Lysate Vaccine Sales Market Share by Type (2019-2024)
Table 53. Global Tetravalent Influenza Virus Lysate Vaccine Sales Market Share by Type (2025-2030)
Table 54. Global Tetravalent Influenza Virus Lysate Vaccine Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Tetravalent Influenza Virus Lysate Vaccine Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Tetravalent Influenza Virus Lysate Vaccine Revenue Market Share by Type (2019-2024)
Table 57. Global Tetravalent Influenza Virus Lysate Vaccine Revenue Market Share by Type (2025-2030)
Table 58. Global Tetravalent Influenza Virus Lysate Vaccine Price (US$/Unit) by Type (2019-2024)
Table 59. Global Tetravalent Influenza Virus Lysate Vaccine Price (US$/Unit) by Type (2025-2030)
Table 60. Global Tetravalent Influenza Virus Lysate Vaccine Sales (K Units) by Application (2019-2024)
Table 61. Global Tetravalent Influenza Virus Lysate Vaccine Sales (K Units) by Application (2025-2030)
Table 62. Global Tetravalent Influenza Virus Lysate Vaccine Sales Market Share by Application (2019-2024)
Table 63. Global Tetravalent Influenza Virus Lysate Vaccine Sales Market Share by Application (2025-2030)
Table 64. Global Tetravalent Influenza Virus Lysate Vaccine Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Tetravalent Influenza Virus Lysate Vaccine Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Tetravalent Influenza Virus Lysate Vaccine Revenue Market Share by Application (2019-2024)
Table 67. Global Tetravalent Influenza Virus Lysate Vaccine Revenue Market Share by Application (2025-2030)
Table 68. Global Tetravalent Influenza Virus Lysate Vaccine Price (US$/Unit) by Application (2019-2024)
Table 69. Global Tetravalent Influenza Virus Lysate Vaccine Price (US$/Unit) by Application (2025-2030)
Table 70. Hualan Vaccine Corporation Information
Table 71. Hualan Vaccine Description and Business Overview
Table 72. Hualan Vaccine Tetravalent Influenza Virus Lysate Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Hualan Vaccine Tetravalent Influenza Virus Lysate Vaccine Product
Table 74. Hualan Vaccine Recent Developments/Updates
Table 75. SINOVAC Corporation Information
Table 76. SINOVAC Description and Business Overview
Table 77. SINOVAC Tetravalent Influenza Virus Lysate Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. SINOVAC Tetravalent Influenza Virus Lysate Vaccine Product
Table 79. SINOVAC Recent Developments/Updates
Table 80. Sanofi Pasteur Corporation Information
Table 81. Sanofi Pasteur Description and Business Overview
Table 82. Sanofi Pasteur Tetravalent Influenza Virus Lysate Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Sanofi Pasteur Tetravalent Influenza Virus Lysate Vaccine Product
Table 84. Sanofi Pasteur Recent Developments/Updates
Table 85. CSL Seqirus Corporation Information
Table 86. CSL Seqirus Description and Business Overview
Table 87. CSL Seqirus Tetravalent Influenza Virus Lysate Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. CSL Seqirus Tetravalent Influenza Virus Lysate Vaccine Product
Table 89. CSL Seqirus Recent Developments/Updates
Table 90. GSK Corporation Information
Table 91. GSK Description and Business Overview
Table 92. GSK Tetravalent Influenza Virus Lysate Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. GSK Tetravalent Influenza Virus Lysate Vaccine Product
Table 94. GSK Recent Developments/Updates
Table 95. Seqirus, Inc. Corporation Information
Table 96. Seqirus, Inc. Description and Business Overview
Table 97. Seqirus, Inc. Tetravalent Influenza Virus Lysate Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Seqirus, Inc. Tetravalent Influenza Virus Lysate Vaccine Product
Table 99. Seqirus, Inc. Recent Developments/Updates
Table 100. Shanghai Institute of Biological Products Corporation Information
Table 101. Shanghai Institute of Biological Products Description and Business Overview
Table 102. Shanghai Institute of Biological Products Tetravalent Influenza Virus Lysate Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Shanghai Institute of Biological Products Tetravalent Influenza Virus Lysate Vaccine Product
Table 104. Shanghai Institute of Biological Products Recent Developments/Updates
Table 105. Key Raw Materials Lists
Table 106. Raw Materials Key Suppliers Lists
Table 107. Tetravalent Influenza Virus Lysate Vaccine Distributors List
Table 108. Tetravalent Influenza Virus Lysate Vaccine Customers List
Table 109. Tetravalent Influenza Virus Lysate Vaccine Market Trends
Table 110. Tetravalent Influenza Virus Lysate Vaccine Market Drivers
Table 111. Tetravalent Influenza Virus Lysate Vaccine Market Challenges
Table 112. Tetravalent Influenza Virus Lysate Vaccine Market Restraints
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Tetravalent Influenza Virus Lysate Vaccine
Figure 2. Global Tetravalent Influenza Virus Lysate Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Tetravalent Influenza Virus Lysate Vaccine Market Share by Type in 2023 & 2030
Figure 4. Aldult Product Picture
Figure 5. Child Product Picture
Figure 6. Global Tetravalent Influenza Virus Lysate Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Tetravalent Influenza Virus Lysate Vaccine Market Share by Application in 2023 & 2030
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Global Tetravalent Influenza Virus Lysate Vaccine Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 11. Global Tetravalent Influenza Virus Lysate Vaccine Market Size (2019-2030) & (US$ Million)
Figure 12. Global Tetravalent Influenza Virus Lysate Vaccine Sales (2019-2030) & (K Units)
Figure 13. Global Tetravalent Influenza Virus Lysate Vaccine Average Price (US$/Unit) & (2019-2030)
Figure 14. Tetravalent Influenza Virus Lysate Vaccine Report Years Considered
Figure 15. Tetravalent Influenza Virus Lysate Vaccine Sales Share by Manufacturers in 2023
Figure 16. Global Tetravalent Influenza Virus Lysate Vaccine Revenue Share by Manufacturers in 2023
Figure 17. The Global 5 and 10 Largest Tetravalent Influenza Virus Lysate Vaccine Players: Market Share by Revenue in 2023
Figure 18. Tetravalent Influenza Virus Lysate Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 19. Global Tetravalent Influenza Virus Lysate Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 20. North America Tetravalent Influenza Virus Lysate Vaccine Sales Market Share by Country (2019-2030)
Figure 21. North America Tetravalent Influenza Virus Lysate Vaccine Revenue Market Share by Country (2019-2030)
Figure 22. United States Tetravalent Influenza Virus Lysate Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 23. Canada Tetravalent Influenza Virus Lysate Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 24. Europe Tetravalent Influenza Virus Lysate Vaccine Sales Market Share by Country (2019-2030)
Figure 25. Europe Tetravalent Influenza Virus Lysate Vaccine Revenue Market Share by Country (2019-2030)
Figure 26. Germany Tetravalent Influenza Virus Lysate Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 27. France Tetravalent Influenza Virus Lysate Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. U.K. Tetravalent Influenza Virus Lysate Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. Italy Tetravalent Influenza Virus Lysate Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Netherlands Tetravalent Influenza Virus Lysate Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Asia Pacific Tetravalent Influenza Virus Lysate Vaccine Sales Market Share by Region (2019-2030)
Figure 32. Asia Pacific Tetravalent Influenza Virus Lysate Vaccine Revenue Market Share by Region (2019-2030)
Figure 33. China Tetravalent Influenza Virus Lysate Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Japan Tetravalent Influenza Virus Lysate Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. South Korea Tetravalent Influenza Virus Lysate Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. India Tetravalent Influenza Virus Lysate Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Southeast Asia Tetravalent Influenza Virus Lysate Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. China Taiwan Tetravalent Influenza Virus Lysate Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Australia Tetravalent Influenza Virus Lysate Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Latin America Tetravalent Influenza Virus Lysate Vaccine Sales Market Share by Country (2019-2030)
Figure 41. Latin America Tetravalent Influenza Virus Lysate Vaccine Revenue Market Share by Country (2019-2030)
Figure 42. Mexico Tetravalent Influenza Virus Lysate Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Brazil Tetravalent Influenza Virus Lysate Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Argentina Tetravalent Influenza Virus Lysate Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa Tetravalent Influenza Virus Lysate Vaccine Sales Market Share by Country (2019-2030)
Figure 46. Middle East & Africa Tetravalent Influenza Virus Lysate Vaccine Revenue Market Share by Country (2019-2030)
Figure 47. Turkey Tetravalent Influenza Virus Lysate Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Saudi Arabia Tetravalent Influenza Virus Lysate Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. UAE Tetravalent Influenza Virus Lysate Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Global Sales Market Share of Tetravalent Influenza Virus Lysate Vaccine by Type (2019-2030)
Figure 51. Global Revenue Market Share of Tetravalent Influenza Virus Lysate Vaccine by Type (2019-2030)
Figure 52. Global Tetravalent Influenza Virus Lysate Vaccine Price (US$/Unit) by Type (2019-2030)
Figure 53. Global Sales Market Share of Tetravalent Influenza Virus Lysate Vaccine by Application (2019-2030)
Figure 54. Global Revenue Market Share of Tetravalent Influenza Virus Lysate Vaccine by Application (2019-2030)
Figure 55. Global Tetravalent Influenza Virus Lysate Vaccine Price (US$/Unit) by Application (2019-2030)
Figure 56. Tetravalent Influenza Virus Lysate Vaccine Value Chain
Figure 57. Tetravalent Influenza Virus Lysate Vaccine Production Process
Figure 58. Channels of Distribution (Direct Vs Distribution)
Figure 59. Distributors Profiles
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
